U.S. License Holder:
Centus / Fujifilm Kyowa Kirin
Date of License:
aBLA accepted by FDA November-2019
FKB238 (bevacizumab) is not FDA-approved. An aBLA has been accepted by the FDA.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
6,586,206 (Methods for Making Recombinant Proteins Using Apoptosis Inhibitors) 7,390,660 (Methods for Growing Mammalian Cells In Vitro) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 9,441,035 (Cell Culture Media and Methods of Antibody Production) 9,795,672 (Treatment with Anti-VEGF Antibodies) 10,017,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,208,355 (Method of Treatment for Glioblastoma by Administering a VEGF Antagonist) 10,336,983 (Method for Increasing the Specific Production Rate of Eukaryotic Cells) 10,662,237 (Method to Improve Virus Filtration Capacity) 10,676,710 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production)
Centus Biotherapeutics Limited; Fujifilm Corporation; Fujifilm Kyowa Kirin Biologics Co., Ltd.; Kyowa Kirin Co., Ltd.